Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.98 |
| ▸ | TSHR | P16473 | 1/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.83 |
| ▸ | MAOA | P21397 | 1/20 | 0.83 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.83 |
| ▸ | DRD2 | P14416 | 1/20 | 0.66 |
| ▸ | DRD1 | P21728 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.60 |
| ▸ | ACHE | P22303 | 1/20 | 0.60 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.57 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.57 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29651290 | 1.00 | TP53 (0.98) | TP53TSHRMAPK1NR1I2MAOA | |
| Hydrochloric Acid SCHEMBL2000082 | 0.99 | TP53 (1.00) | TP53TSHRMAPK1NR1I2MAOA | |
| Methopholine SCHEMBL26169 | 0.91 | NR1I2 (1.00) | TP53TSHRMAPK1NR1I2MAOA | |
| Methopholine SCHEMBL30492235 | 0.91 | NR1I2 (1.00) | TP53TSHRMAPK1NR1I2MAOA | |
| SCHEMBL20683170 | 0.89 | DRD2 (0.79) | TP53TSHRMAPK1NR1I2MAOA | |
| SCHEMBL8200503 | 0.89 | TP53 (0.78) | TP53TSHRMAPK1NR1I2MAOA | |
| SCHEMBL30163297 | 0.83 | TP53 (0.70) | TP53TSHRMAPK1NR1I2MAOA | |
| SCHEMBL29373104 | 0.81 | DRD2 (0.89) | TP53TSHRMAPK1DRD2DRD1 | |
| SCHEMBL8203917 | 0.81 | NR1I2 (0.80) | TP53TSHRMAPK1NR1I2MAOA | |
| (S)-Reticuline SCHEMBL147597 | 0.80 | DRD2 (1.00) | MAPK1DRD2DRD1BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5952344-A | TREATING AND CONTROL OF DISEASES WHICH REPRESENT THERAPEUTIC INDICATIONS FOR NMDA(N-METHYL-D-ASPERTATE) RECEPTOR SUBTYPE SPECIFIC BLOKERS BY ADMINISTERING TETRAHYDROISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 1999-09-14 | — | — | US | claimed |
| EP-0787493-A1 | Tetrahydroisoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-06 | — | — | EP | claimed |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPITAL | 2024-05-16 | — | — | US | disclosed |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | RHODE ISLAND HOSPITAL (US) | 2023-07-18 | — | — | US | disclosed |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-01-28 | — | — | US | disclosed |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | RHODE ISLAND HOSPITAL | 2020-12-03 | — | — | US | disclosed |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2020-02-11 | — | — | US | disclosed |
| WO-2019191151-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | RHODE ISLAND HOSPTIAL (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20180193344-A1 | Nanocarriers And Their Processing For Diagnostics And Therapeutics | RHODE ISLAND HOSPITAL | 2018-07-12 | — | — | US | disclosed |
| US-9775842-B2 | Nanocarriers and their processing for diagnostics and therapeutics | RHODE ISLAND HOSPITAL (US) | 2017-10-03 | — | — | US | disclosed |
| US-20120208848-A1 | GACYCLIDINE FORMULATIONS | NEUROSYSTEC CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120171121-A1 | Rosette Nanotubes as Drug Delivery Agents | BROWN UNIVERSITY (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011076946-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALZHEIMER | Universidad Del País Vasco (ES) | 2011-06-30 | — | — | WO | disclosed |
| EP-2338492-A1 | Methods and compositions for the treatment of alzheimer | Universidad del Pais Vasco (ES) | 2011-06-29 | — | — | EP | disclosed |
| US-20060264897-A1 | Apparatus and method for delivering therapeutic and/or other agents to the inner ear and to other tissues | NEUROSYSTEC CORPORATION (US) | 2006-11-23 | — | — | US | disclosed |
| US-20060205789-A1 | Gacyclidine formulations | NEUROSYSTEC CORPORATION (US) | 2006-09-14 | — | — | US | disclosed |
| US-6071929-A | SELECTIVE BLOCKERS OF N-METHYL-D-ASPARTIC ACID FOR TEATMENT OF NERVOUS SYSTEM AND BRAIN DISORDERS OR INJURIES | HOFFMAN-LA ROCHE INC. (US) | 2000-06-06 | — | — | US | disclosed |
| US-5952344-A | TREATING AND CONTROL OF DISEASES WHICH REPRESENT THERAPEUTIC INDICATIONS FOR NMDA(N-METHYL-D-ASPERTATE) RECEPTOR SUBTYPE SPECIFIC BLOKERS BY ADMINISTERING TETRAHYDROISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0787493-A1 | Tetrahydroisoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1997-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120171121-A1 | Rosette Nanotubes as Drug Delivery Agents | EPHA2, CD44, HDGF | TP53 155/4885TSHR 2096/4885MAPK1 3450/4885 |
| US-12357635-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | TP53 150/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-20180193344-A1 | Nanocarriers And Their Processing For Diagnostics And Therapeutics | SYVN1, SSB, TNF | TP53 150/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-11701379-B2 | In vitro and in vivo intracellular delivery of siRNA via self-assembled nanopieces | NFATC1, TRAF6, UACA | TP53 277/4885TSHR 2583/4885MAPK1 2376/4885 |
| US-20210023117-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | TP53 277/4885TSHR 2583/4885MAPK1 2376/4885 |
| US-10555948-B2 | Nanocarriers and their processing for diagnostics and therapeutics | SYVN1, SSB, TNF | TP53 150/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-20120208848-A1 | GACYCLIDINE FORMULATIONS | DCTD, TYMP, TYMS | TP53 2310/4885TSHR 3429/4885MAPK1 2605/4885 |
| US-20200375991-A1 | NANOCARRIERS AND THEIR PROCESSING FOR DIAGNOSTICS AND THERAPEUTICS | SYVN1, SSB, TNF | TP53 150/4885TSHR 2826/4885MAPK1 4133/4885 |
| US-20240156853-A1 | IN VITRO AND IN VIVO INTRACELLULAR DELIVERY OF SIRNA VIA SELF-ASSEMBLED NANOPIECES | NFATC1, TRAF6, UACA | TP53 277/4885TSHR 2583/4885MAPK1 2376/4885 |
| US-20060205789-A1 | Gacyclidine formulations | DCTD, TYMP, TYMS | TP53 2310/4885TSHR 3429/4885MAPK1 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.